|Articles|September 17, 2020
Nitrosamine Testing: The Regulatory Aspects
Author(s)SGS
Detection of N-Nitrosodimethylamine (NDMA) impurities has led to regulatory warnings and product recalls. Pharmaceutical manufacturers must adopt a proactive approach to risk assessment and mitigation in relation to genotoxic contaminants.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Industry Outlook 2026: Trends Transitioning from 2025 into 2026
2
Building the Foundations for Proactive Drug Safety in 2026
3
Amgen Acquires UK Biotech Dark Blue Therapeutics
4
Genetic Medicines Project Gets Funding from UKRI Innovate UK and Canadian NRC IRAP
5